Paul Toren

Nadir Testosterone Within First Year of Androgen-Deprivation Therapy (ADT) Predicts for Time to Castration-Resistant Progression: A Secondary Analysis of the PR-7 Trial of Intermittent Versus Continuous ADT

Laurence Klotz, Chris J. O’Callaghan, Keyue Ding et al. · Journal of Clinical Oncology · 2015 · 165 citations · Full text

Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models

Paul Toren, Soojin Kim, Thomas Cordonnier et al. · European Urology · 2014 · 107 citations

Urology, Preclinical Models, Medicine +7

Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer

Paul Toren, Soojin Kim, Steven Pham et al. · Molecular Cancer Therapeutics · 2014 · 95 citations

Androgen Receptor, Oral Vt-464 Treatment, Castrate-resistant Prostate Cancer +18

Plasma extracellular vesicles as phenotypic biomarkers in prostate cancer patients

France‐Hélène Joncas, Fabrice Lucien, Mélanie Rouleau et al. · The Prostate · 2019 · 77 citations

Small Incidentally Discovered Testicular Masses in Infertile Men—Is Active Surveillance the New Standard of Care?

Paul Toren, Matthew Roberts, Irene Lecker et al. · The Journal of Urology · 2010 · 75 citations